NCT04248829 2026-05-28Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)Yuhan CorporationPhase 3 Completed393 enrolled 13 charts